Table 1. Baseline and demographic factors in cases with severe hepatocellular injury and concurrent controls.
| Cases (n=88) |
Controls (n=6137) |
p-value | |
|---|---|---|---|
| Age at transplant | 0.9764 | ||
| Mean ± SD | 40.6 ± 15.8 | 40.4 ± 17.1 | |
| Median (range) | 45.3 (2 - 68) | 43.3 (0 - 78) | |
| Male patients | 52 (59.0%) | 3433 (55.9%) | 0.5898 |
| Primary diagnosis | 0.4805 | ||
| Hematologic malignancies (non-lymphoma) | 48 (54.5%) | 3165 (51.6%) | |
| Lymphoma | 17 (19.3%) | 1027 (16.7%) | |
| Other malignancy | 17 (19.3%) | 1616 (26.3%) | |
| Other than malignancy | 6 (6.8%) | 328 (5.3%) | |
| Second or more HCT | 10 (11.4%) | 594 (9.7%) | 0.5848 |
| Allogeneic transplant | 62 (70.5%) | 4328 (70.5%) | 1.000 |
| Source of donor cells (allogeneic HCT only) | 0.3713 | ||
| Peripheral blood stem cells | 31 (50%) | 1940 (45%) | |
| Bone marrow | 31 (50%) | 2388 (55%) | |
| Other than HLA identical sibling donor (allogeneic HCT only) | 35 (56.5%) | 2487 (57.5%) | 0.8975 |
| Conditioning regimen | |||
| Myeloablative regimen1 | 81 (92.0%) | 5395 (87.9%) | 0.1835 |
| Reduced intensity regimen | 7 (8.0%) | 742 (12.1%) | |
| Positive CMV serostatus at transplant (donor or recipient) | 48 (54.6%) | 3940 (64.5%) | 0.0570 |
| Ursodiol prophylaxis | 19 (21.6%) | 1661 (27.1%) | 0.2779 |
1
Includes regimens received by 3 patients whose severe hepatocellular injury occurred later, following infusion of gemtuzumab ozogamicin for treatment of recurrent leukemia after transplant.18